OPKO Health (NASDAQ:OPK) CEO Phillip Md Et Al Frost Purchases 533,300 Shares of Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost purchased 533,300 shares of the company’s stock in a transaction on Tuesday, November 18th. The shares were purchased at an average price of $1.27 per share, for a total transaction of $677,291.00. Following the purchase, the chief executive officer owned 214,966,448 shares in the company, valued at approximately $273,007,388.96. The trade was a 0.25% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Friday, October 31st, Phillip Md Et Al Frost bought 150,000 shares of OPKO Health stock. The shares were purchased at an average cost of $1.42 per share, with a total value of $213,000.00.

OPKO Health Price Performance

Shares of NASDAQ OPK opened at $1.28 on Wednesday. OPKO Health, Inc. has a 52 week low of $1.11 and a 52 week high of $2.04. The business’s 50 day moving average price is $1.44 and its 200 day moving average price is $1.37. The company has a quick ratio of 3.02, a current ratio of 3.41 and a debt-to-equity ratio of 0.25. The firm has a market cap of $982.66 million, a P/E ratio of -5.12 and a beta of 1.50.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $0.03 EPS for the quarter, beating the consensus estimate of ($0.02) by $0.05. The business had revenue of $151.67 million during the quarter, compared to analysts’ expectations of $165.74 million. OPKO Health had a negative net margin of 28.10% and a negative return on equity of 13.62%. The business’s quarterly revenue was down 12.6% compared to the same quarter last year. During the same period in the previous year, the business posted $0.03 EPS. On average, sell-side analysts expect that OPKO Health, Inc. will post -0.25 earnings per share for the current year.

Hedge Funds Weigh In On OPKO Health

Hedge funds have recently bought and sold shares of the business. Oak Thistle LLC purchased a new stake in shares of OPKO Health in the first quarter valued at approximately $26,000. Caprock Group LLC acquired a new stake in OPKO Health in the 3rd quarter valued at $26,000. GM Advisory Group LLC purchased a new stake in OPKO Health in the 1st quarter worth $33,000. Savant Capital LLC acquired a new position in OPKO Health during the third quarter worth $33,000. Finally, Cerity Partners LLC purchased a new position in OPKO Health during the first quarter valued at $36,000. Hedge funds and other institutional investors own 64.63% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on OPK. Barrington Research reaffirmed an “outperform” rating and issued a $2.25 price target on shares of OPKO Health in a report on Thursday, October 30th. Zacks Research upgraded OPKO Health from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 14th. Wall Street Zen raised OPKO Health from a “strong sell” rating to a “hold” rating in a report on Saturday, November 1st. Jefferies Financial Group reissued a “hold” rating and issued a $1.60 price target (down from $2.00) on shares of OPKO Health in a report on Thursday, October 30th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of OPKO Health in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, OPKO Health has an average rating of “Hold” and a consensus price target of $2.28.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.